相关文献的矩形ASCII编码数据(Rectangular ASCII files for relevant paper)_算法理论_科研数据集
- 格式：pdf
- 大小：92.02 KB
- 文档页数：4
相关文献的矩形ASCII编码数据(Rectangular ASCII
files for relevant paper)
数据摘要：
In the accompanying data file we provide the data used in the paper as
two rectangular ASCII files. The data are stripped of patient identifiers.
中文关键词：
长方形的,ASCII 文件,算法,统计,
英文关键词：
rectangular,ASCII files,algorithm,statistic,
数据格式：
TEXT
数据用途：
design of the algorithm
数据详细介绍：
Rectangular ASCII files for relevant paper
In the accompanying data file we provide the data used in the paper as two
rectangular ASCII files. The data are stripped of patient identifiers.
File 'data.txt'
The first 2 lines are headers. Records the WBC responses as a (3096 x 3)
matrix with columns
1. patient number (1 through 608)
2. log white blood cell count, in log thousands, log(WBC/1000)
3. day within 1st cycle (negative numbers are before day 1 of the protocol)
File 'pat.txt'
The first 2 lines are headers. Records patient characteristics as a (608 x 5)
matrix with columns
1. patient number (1 through 608)
2. study identifier (1 = CALGB 8881, 2=CALGB 9160, 3=CALGB 8541)
3. dose cyclophosphamide (for 8881 and 9160) For 8541 we record -1 (see
comments above)
4. dose GM/CSF (for 8881 and 9160) For 8541 we record -1 (see comments
above)
5. Number of observations for this patient
CONSISTENCY CHECKS
As a simple check that you read the data correctly,
-- Verify that the sum of ni ('pat.txt', column 5) equals the total number of lines
in 'data.txt'. It should be n=3096.
-- The total number of patients should be N=608.
-- Following are min, max and mean of log WBC ('data.txt', column 2), CTX
('pat.txt', column 3)and GM-CSF ('pat.txt', column 4): min max mean WBC
-2.996 4.355 1.15644 CTX -1.000 6.000 -0.32566 GM -1.000 10.000 0.08882
CALGB has kindly agreed to make these data available for interested readers,
subject to the following conditions:-
-- Any paper using these data should acknowledge CALGB for the use of the
data.
-- The paper should reference the original papers describing the studies:
CALGB 8541
Wood, W., Budman, D., Korzun, A., Cooper, M., Younger, J., Hart, R., Moore,
A., Ellerton, J., Norton, L., Ferree, C., Ballow, A., Ill, E. and Henderson, I.
(1994) "Dose and dose intensity of adjuvant chemotherapy for stage ii, node
positive breast cancer." New England Journal of Medicine, 330, 1253--1259.
CALGB 8881
Lichtman, S. M., Ratain, M. J., Echo, D. A., Rosner, G., Egorin, M. J., Budman,
D. R., Vogelzang,N. J., Norton, L. and Schilsky, R. L. (1993) "Phase I trial and
granulocyte-macrophage colony-stimulating factor plus high-dose
cyclophosphamide given every 2 weeks: a Cancer andLeukemia Group B
study." Journal of the National Cancer Institute, 85, 1319--1326.
CALGB 9160
Budman, D., Rosner, G., Lichtman, S., Miller, A., Ratain, M. and Schilsky, R.
(1998) "A randomized trial of wr-2721 (amifostine) as a chemoprotective agent
in combination with high-dose cyclophosphamide and molgramostim
(GM-CSG)."Cancer Therapeutics, 1, 164--167.
数据预览：
点此下载完整数据集
